Page 15 - Vaccine

Our goal is to have HPV vaccination as part of State mission: MSD India MD

In a Q&A, Rehan A Khan talks about his firm's strong focus on R&D and its commitment to making drugs affordable

Bharat Biotech's Covaxin induces wider immune response, say experts

However, experts say that Covaxin induces a wider immune response and thus antibody production against the spike protein may be less intense

India supported TRIPS waiver for benefit of developing nations: Goyal

According to the minister, India has a number of Covid vaccines and can help other developing countries to make vaccines

Covishield booster post Covaxin priming improves immune response 58x: CMC

So far, India has not allowed heterologous boosting of vaccines

WTO's vaccine patent waiver may have little impact on ground now: Industry

Serum Institute says while patent waivers for Covid-19 vaccines are 'encouraging', demand for vaccines today is declining

Monkeypox bite: Bavarian Nordic is becoming a 'hot stock' again

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May

Vaccine makers claims efficacy against Omicron variant of Covid-19

Omicron has been the dominant strain across the world since January, quickly replacing the Delta variant that had caused a devastating second wave in India

WHO to share vaccines to stop monkeypox outbreak amid inequity fears

The move could result in the U.N. health agency distributing scarce vaccine doses to rich countries that can otherwise afford them.

EU signs deal to buy almost 110K doses of Danish vaccine to curb monkeypox

The European Union (EU) has signed a deal with Danish manufacturer Bavarian Nordic for the purchase of 109,090 doses of vaccine to curb the spread of monkeypox

Shot in the arm for boosters: Demand jumps 20% as Covid cases spike

On Saturday, the daily vaccination in the state touched 100,000, said Sachin Desai, state immunisation officer

Jubilant to double injectable capacity in US at a cost of $193 mn

Signs agreement with US biomedical dept

Bharat Biotech's Covaxin phase-3 trial concluded successfully at AMU

The phase-3 trial for Covaxin was done in collaboration with the Indian Council of Medical Research (ICMR) and BBIL

Adani calls global cooperation 'facade', pitches for self-reliant India

Collaborations not condescension is key to the new world order, he said, adding self-defence and self-reliance preoccupy war-wary leaders in Davos

Pfizer to offer nearly two dozen low-cost products to poor nations

The products, which are widely available in the US and the European Union, include 23 medicines and vaccines that treat infectious diseases, some cancers and rare and inflammatory conditions

Serum Institute likely to launch cervical cancer vaccine in India in Nov

Country now depends on foreign companies and Serum's product is likely to bring down prices.

UK brings in 21-day isolation measures to contain monkeypox spread

Smallpox vaccines are around 85 per cent effective in preventing monkeypox infection, and several countries have said they have begun stockpiling them

India-developed 'variant-proof' Covid vaccine likely in 2-3 years: Industry

Domestically produced variant-proof jabs are part of a global project to develop vaccines for future epidemics

Biological E plans to ramp up non-vaccines business in next three years

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

With mRNA vaccine, India will have flexibility against Covid-19: Scientist

The Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) recently announced the development of the country's first potential mRNA vaccine candidate to fight against SARS-CoV-2

SII, Symbiosis to set up research centre for vaccine development

Serum Institute of India on Friday said it has signed an agreement with the Symbiosis International University earlier this month to set up a research centre for vaccines and biologicals. The R&D (Research & Development) centre will lead the development of new vaccines, technologies, products and innovations in immunisation practices that provide equitable access to life-saving interventions, especially across Low- and Middle-Income Countries (LMICs). The entity will work towards improving health equity against future pandemics and infectious diseases. It will also ensure cross-programme coordination and collaboration, as the facility will be an ecosystem that would also have R&D centres for stem cells, nanotechnology, medical image analysis, applied artificial intelligence and waste resource management, among others. "The research centre will be instrumental in advancing indigenous capabilities for end-to-end development of any futuristic technology and projects in the ...